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Inflammation is an important event in the development of vascular diseases such as hypertension, 
atherosclerosis, and restenosis. The stimulation of lipopolysaccharide (LPS) from bacteria induces the 
release of critical proinflammatory cytokines that activate potent immune responses which may cause 
injury of cells in vivo and in vitro. Upon cardiac cell death caused by inflammation, the apoptotic 
cardiac cells express higher amount of cardiac markers. In this study, the effect of various LPS on 
human cardiac fibroblasts (HCFs) and human coronary smooth muscle cells (HCSMCs) were evaluated. 
Various forms of LPS were applied to HCFs and HCSMCs for 24, 48, 72 and 96 h. Proliferation rate of 
these cells was evaluated after stimulation. The levels of lactate dehydrogenase (LDH), N-terminal pro 
B-type natriuretic peptide (pro-BNP) and the MB isoenzyme of creatine kinase (CK-MB) were measured 
by an automation system. Cytokine levels in culture supernatants and extracted protein of cells were 
mixed and measured with IL-1β, IL-6 and IL-10 ELISA kits. Significant increase in the proliferation of two 
cardiac cells (P<0.05) after incubation for 48 and 72 h was noted but not for 24 and 96 h (P>0.05). 
Cardiac markers and inflammatory cytokines were significantly higher than control at 48 and 72 h 
(P<0.05), which demonstrated that HCFs and HCMSCs were under inflammation leading to cell injury 
between 48 and 72 h. LPS is one of the factors giving rise to periodontal diseases, it is also involved in 
in vitro cardiac cell injury. Therefore, LPS may be used as a bio-marker to monitor local or systemic 
inflammation.  
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The heart tissues consist of cardiomyocytes, fibroblasts 
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fibroblast  cells  are  diverse  and  experimental  evidence 
has shown that substantial heterogeneity exists between 
fibroblasts and different tissues (Brown et al., 2005). The 
human cardiac fibroblast (HCF) is one of the two major 
cell types of the heart; combination of the cardiomyocytes 
regulates the normal cardiac function. They are the  main 




components of extracellular matrix that regulate the 
function of the heart including the chemical, physical and 
electrical signals (Kamkin  et  al.,  2003;  Camelliti  et  al., 
2005; Porter and Turner, 2009). HCFs are also respon-
sible for the synthesis of vital extracellular matrix 
products in the heart, including fibrillar collagen types I 
and type III (Myllyharju and Kivirikko, 2001; Lijnen et al., 
2003). The human coronary smooth muscle cells invent 
from progenitors in the proepicardial organ, a transitory 
organization formed by mesothelial cells overlying the 
sinus venous, they are responsible for the inward and 
departing blood flow (Lam et al., 2009). 
Lipopolysaccharide (LPS) is an eminently effective 
inflammatory immune activator, a key constituent of the 
various bacteria cell walls especially in Gram-negative 
strains (Ulevitch and Tobias, 1999). It functions to steady 
the general membrane structure and to prevent it from 
certain chemical attack. It can stimulate the production of 
endogenous pyrogen IL-1 and tumor necrosis factor 
(Beutler, 2002; Stawowy et al., 2003). LPS is the most 
powerful bacterial product in terms of its pro-inflammatory 
activities. Stimulation of innate immune system or 
immune cells in vitro by LPS, could lead to uncontrollable 
cytokines and other mediators production, which may 
cause various inflammatory diseases in the human body 
(Lu et al., 2009). 
Porphyromonas gingivalis (P. gingivalis), a Gram-
negative bacterium strongly associated with periodontitis, 
which is a chronic inflammatory disease of the tissue 
surrounding the tooth root surface (Paquette, 2002). It is 
suspected that both the bacterial factors, such as P. 
gingivalis and host factors have effects on such disease 
(Al-Qutub et al., 2006). Studies also suggest that there is 
an association between periodontitis and systemic 
diseases such as coronary heart disease and preterm 
birth (Paquette, 2002). LPS obtained from P. gingivalis is 
atypical, as it exhibits bizarre quantities of lipid A 
heterogeneity including both tetra- and penta-acylated 
lipid A structures (Bainbridge et al., 2002; Darveau, 2004; 
Yi, 2000; Lu et al., 2009). Designated P. gingivalis 
LPS1690, a major monophosphoryl penta-acylated lipid A 
cluster is observed, when incubated at 1 µg/ml haemin 
which is a microenvironmental component for P. 
gingivalis that can modulate the lipid A structure found in 
a bacterium (Al-Qutub et al., 2006). P. gingivalis LPS1435 
is observed at higher haemin concentrations (Al-Qutub et 
al., 2006). Penta-acylated lipid A structures have been 
demonstrated to assist E-selectin expression, but tetra-
acylated lipid A structures do not present similar function 
(Lu et al., 2009). Multiple lipid A structures that may stand 
for an alteration made by P. gingivalis in reaction to the 
modification of systemic or local host micro-environments 
(Lu et al., 2009).  
At present, little information is available on how these 
isoforms of P. gingivalis LPS could differentially affect 
host innate immune responses. LDH is an isoenzyme not 
only specific for measuring cardiac cells damage, but also 





damage in systemic human body (Wang et al., 2007; 
Totlandsdal et al., 2008). An association with  high  levels 
of LDH and changes in the ratio of LDH usually indicates 
some type of tissue damage or death (Wang et al., 2007; 
Totlandsdal et al., 2008). CK-MB is an enzyme posses-
sed by several tissues and cell types useful for the 
determination of cardiac problems (Wallimann and 
Hemmer, 1994), which is expressed in cardiac muscles 
and BB-CK is expressed in smooth muscles and in most 
non-muscle tissue. When levels of this enzyme is high, 
the individual is susceptible to cardiac damage as in 
troponin T, it is commonly found to be relatively low in 
systemic circulation in humans (Wallimann and Hemmer, 
1994). The pro-BNP acts as a cardiac marker that is an 
indicator of a decline in systemic vascular resistance and 
central venous pressure; therefore, it is an indicator to a 
decrease in cardiac output (Atisha et al., 2004). This 
cardiac marker is used in the diagnosis of congestive 
heart failure, and has been proved practical in the 
projection of heart failure when the pro-BNP level is 
found to be higher in patients exhibiting worse outcomes. 
Interleukin is a generic term for a group of multi-
functional cytokines produced by a large variety of body 
cells responsible for the regulation of the immune system, 
by facilitating communication between immune cells used 
to contest against detrimental substances such as 
bacteria through chemical signals (Razelle, 1996). Due to 
the large number of different interleukins, it is clear that 
each one is unique to its function yielding many different 
purposes (Razelle, 1996). IL-1β, a cytokine responsible 
for the stimulation of inflammation, is involved in the 
proliferation, differentiation and apoptosis of cells 
(Gurantz et al., 2005). IL-6 is responsible for program-
ming cytokine designed for inflammation and the 
maturation of B cells most commonly produced at sites of 
severe and chronic inflammation, where it is secreted into 
the serum and induces a transcriptional inflammatory res-
ponse through interleukin 6 receptor alpha (Du et al., 
2005; Turner et al., 2008). IL-10, a type of cytokine 
known for its anti-inflammatory properties, counteracts in-
flammatory cytokines such as “IL-1Β and IL-6 by 
activated macrophages (Berlato et al., 2002).
 
 
The purpose of this study was to investigate how the 
application of various lipopolysaccharide (LPS): P. 
gingivalis wild type LPS, P. gingivalis LPS1690, P. 
gingivalis LPS1435 and Escherichia coli LPS affect the 
activity, cytokines expression and cardiac bio-markers 
release of human cardiac fibroblasts and human coronary 




MATERIALS AND METHODS 
 
LPS Preparation  
 
P. gingivalis LPS was isolated from P. gingivalis ATCC 33277 and 
prepared by the cold MgCl2-ethanol procedure, based upon the 





successive solubilisation and precipitation procedures (Lu et al., 
2009). The  LPS  was  supplementarily  purified  to  eliminate  trace 
amounts of endotoxin protein; the final protein contamination was 
less than 0.1%. The fatty acids present in the P. gingivalis LPS 
were analyzed by gas chromatography-mass spectroscopy (Lu et 
al., 2009). Three separate extractions of P. gingivalis LPS were 
obtained, including P. gingivalis wild type LPS (m/z 1690) (P. 
gingivalis wild type LPS), P. gingivalis 1587KO (m/z 1690) (P. 
gingivalis LPS1690) and P. gingivalis 1773KO (m/z 1435/50) (P. 
gingivalis LPS1435). E. coli O55:B5 LPS was purchased from Sigma 
(St Louis, MO, USA). All types of LPS were diluted by Hanks' 
Balanced Salt Solution (HBSS) (St Louis, MO, USA) in the 
stimulation tests before use. 
 
 
Cardiac cells culture and pilot study of LPS 
 
Human cardiac fibroblasts (HCF, adult ventrical, Catalog# 6310) 
were purchased from ScienCell Research Laboratory (San Diego, 
CA, USA) and Human Coronary Smooth Muscle Cells (HCSMCs) 
were purchased from Cascade Biologics (Cascade Biologics Inc., 
OR, USA). HCFs and HCSMCs were cultured in Dulbecco’s 
Modified Eagle Medium and Dulbecco’s Modified Eagle Medium/ 
Ham’s F12 (1:1), respectively, both containing 10% fetal bovine 
serum, 100 U/ml penicillin G and 100 mg/ml streptomycin 
(Invitrogen, Hong Kong) at 37°C in a humidified atmosphere of 95% 
air, 5% CO2. The cells used in this study were from the early 
passages 2 to 6, to limit the possible variations in LPS stimulation 
(Li et al., 2009). 
The two cardiac cells (between passages 2 and 6) were seeded 
in 96-well culture plates (Nalge Nunc International Corp., IL, USA) 
for 24, 48, 72 and 96 h in the presence or absence of various LPS 
(P. gingivalis wild type LPS, P. gingivalis LPS1435 and P. gingivalis 
LPS1690 at 1, 10, and 100 ng/ml; E. coli LPS at 100 µg/ml, 10 µg/ml, 
1 µg/ml, 100 ng/ml, 10 ng/ml and 1 ng/ml) to conduct a pilot study 
to determine the optimal stimulating time and LPS concentrations. 
After preliminary experiments, 100 ng/ml has been found to induce 
cardiac markers and cytokines expression in both cell lines for P. 
gingivalis wild type LPS, P. gingivalis LPS1435, LPS1690 and E. coli 
LPS at 48 and 72 h.  
 
 
Proliferation rate measured by WST-1 for cardiac cells after 
stimulation with LPSs 
 
The activity of LPSs were assessed with cell proliferation reagent 
WST1 (Roche, Mannheim, Germany) using HCF and HCSMC cell 
lines in the pilot and final experiments. Cells were cultured at a 
density of 4000 cells per well into 96-well microtitre plates (Nalge 
Nunc International Corp., IL, USA). At the designated time-points 
being 48 and 72 h after inoculation, 10 µl WST1 was applied to 
each well and incubated for 60 min at 37°C. The optical density was 
read at 450 nm by Universal Microplate Reader (Sunrise, TECAN, 
Austria). Each sample was analysed in triplicates. 
 
 
Cardiac markers measurement 
 
The cells were plated at a density of 5 x 105 cells/well into a 6-well 
plate (Nalge Nunc International Corp., IL, USA) in different groups 
as the aforestated condition. At harvest time points, the culture 
medium had been collected and the cells were applied by standard 
trypsinization (0.5 mg/ml trypsin and 0.2 mg/ml EDTA in phosphate 
buffered saline (PBS)), then the cells were washed with PBS, and 
cell pellets were digested, isolated and purified to get proteins by a 
Total Protein Extraction Kit (Millipore Corp., MA, USA). 
The cultured cell lysate and culture medium of these two kinds of 
cells were used  to measure  the  levels  of  lactate  dehydrogenase  




(LDH), N-terminal pro B-type natriuretic peptide (pro-BNP) and the 
MB isoenzyme of creatine kinase (CK-MB) by using an automation 
closed kit system in COBAS INTEGRA 400 PLUS and ELECSYS 
2010 immunoassay analysers (ROCHE, Germany). The marker 
levels were obtained by comparing with the standard curve 
generated from the standards provided by the manufacturer. 
 
 
Enzyme-linked immunosorbent assay (ELISA) measurement on 
soluble IL-1β, IL-6 and IL-10 from cells  
 
The cytokine levels were measured by using cell cultured medium 
and isolated protein from cardiac cells to determine the ability of 
different types of LPS to stimulate HCFs and HCSMCs. Cytokine 
levels in culture supernatants and extracted protein of cells were 
mixed and measured with IL-1β, IL-6, IL-10 ELISA kits (Diaclone, 
France), following the manufacturer’s instructions from the kits. 100 
µl mix of the soluble protein was incubated into a micro-plate 
provided. The plate was incubated for 2 h at 350 rpm and washed 
with washing buffer. Then the wells were dried and 200 µl of 
substrate tetramethylbenizidine was added into each well in the 
dark at room temperature. The plates were then read at 450 nm 
wavelength using microplate reader (Sunrise, TECAN, Austria). The 
levels of cytokines in the samples were obtained by comparison 
with the standard curve generated from standards supplied by the 





Data are reported as mean±SD and all statistical analyses were 
performed using SPSS 15.0. Data were analyzed using the one 
way ANOVA and student’s t test. Differences between the 
experimental and control groups were regarded as statistically 





The influence of different isoforms of LPS on the 
proliferation of two types of cardiac cells in the pilot 
study 
 
In the pilot study, we found that the optimal concentration 
of P. gingivalis wild type LPS, P. gingivalis LPS1435, 
LPS1690 and E. coli LPS was 100 ng/ml. This was deter-
mined as they were the optimal concentration demon-
strating a statistical difference between the control and 
test groups (P<0.05) (Figures 1 and 2). 
 
 
The influence of various LPS on the proliferation of 
human cardiac fibroblasts (HCFs) and human 
coronary smooth muscle cells (HCSMSs)  
 
After determining the optimal concentration of different 
types of LPS in the pilot study, the influence of P. 
gingivalis wild type LPS, P. gingivalis LPS1435, LPS1690 
and E. coli LPS on the proliferation of two cardiac cells 
were also evaluated. There was a significant increase in 
the two cardiac cells proliferation (P<0.05) after incuba-
tion for 48 and 72 h as shown in the final experiments 
(Table 1). However, the cell  proliferation  rate of  the  test  






Figure 1. The cell proliferation of human cardiac fibroblast after stimulation with various LPS for 72 h. 
Groups: (1) control;( 2) Wild type LPS 1 ng; (3) Wild type LPS 10 ng; (4) Wild type LPS 100 ng; (5) P. 
gingivalis LPS1435 1 ng; (6) P. gingivalis LPS1435 10 ng; (7) P. gingivalis LPS1435 100 ng; (8) P. gingivalis 
LPS1690 1 ng; (9) P. gingivalis LPS169010 ng; (10) P. gingivalis LPS1690 100 ng; (11) E. coli LPS 100 µg; 
(12) E. coli LPS 10 µg; (13) E. coli LPS 1 µg; (14) E. coli LPS 100 ng; (15) E. coli LPS 10 ng; (16) E. 




groups was slightly higher than the control group after 24 




The influence of various LPS on the release of 
different markers of HCFs and HCSMSs  
 
To explore the specific effect of LPS on the two cardiac 
cells, we also evaluated the various cardiac markers in 
the two types of cells. Cardiac markers (LDH, NT pro-
BNP and CK-MB) and cytokine levels (IL-6 and IL-1β) of 
HCFs from 48 to 72 h for different types of LPS (P<0.05) 
(Table 2). The same trend was observed in HCSMs, the 
levels of cardiac markers and pro-inflammatory cytokines 
at 72 h were significantly higher than that at 48 h 





It is known that heart diseases  such  as  atherosclerosis,  
hypertension and sepsis-induced myocardial dysfunction, 
result from the stimulation of host cells by bacterial LPS 
(Morrison and Ulevitch, 1978; Aoyagi and Izumo, 1993; 
Heo et al., 2008). LPS stimulation leads to the expression 
and release of a portfolio of markers and proinflammatory 
cytokines and lipid mediators, which in turn can initiate a 
chain of events. In addition, it was reported recently that 
LPS can induce HCSMCs proliferation and inflammation 
which contributes to the development of atherosclerosis 
(Yang et al., 2005; Li et al., 2007). 
However, little is known about the effect of various 
types of LPS in HCFs and HCSMCs. Robert et al. (1997) 
reported that P. gingivalis LPS and E. coli LPS could 
induce white blood cells proliferation, cytokine and CD14 
production, they may act as a regulatory factor in the 
chronic periodontal inflammatory response (Roberts et 
al., 1997). Some isoforms of P. gingivalis LPS and E. coli 
LPS could demonstrate different effects on host immune 
responses in the human body (Lu et al., 2009). One study 
reported that the  P.  gingivalis  LPS1435  does  not  initiate 
endothelial cell by using Toll-like receptor 4 (TLR4); 
however, P. gingivalis LPS1690 and E. coli LPS were both



























Effect   LPS on HCF (72 h) 






Figure 2. The cell proliferation of human coronary smooth muscle cells after stimulation with 
various LPS for 72 h. Groups: (1) control; (2) Wild type LPS 1 ng, (3) Wild type LPS 10 ng; (4) Wild 
type LPS 100 ng; (5) P. gingivalis LPS1435 1 ng; (6) P. gingivalis LPS1435 10 ng; (7) P. gingivalis 
LPS1435 100 ng; (8) P. gingivalis LPS1690 1 ng; (9) P. gingivalis LPS169010 ng; (10) P. gingivalis 
LPS1690 100 ng; (11) E. coli LPS 100 µg; (12) E. coli LPS 10 µg; (13) E. coli LPS 1 µg (14) E. coli 




Table 1. Proliferation rate (mean±SD) of human cardiac fibroblasts (HCF) and 
human coronary smooth muscle cells (HCSMC) after stimulation with various LPS 
for 48 and 72 h.   
 
Group 48 h 72 h 
HCF 
Control 1.1345(±1.41) 0.12620(±0.06) 
Wild type LPS 100 ng/ml 1.2511(±1.92)* 0.33178(±0.08) 
P. gingivalis LPS1435 100 ng/ml 1.2559(±1.88)* 0.35985(±0.05) 
P. gingivalis LPS1690 100 ng/ml 1.2883(±1.67)* 0.18848(±0.04) 
E. coli LPS 100 ng/ml 1.3715(±2.09)* 0.29732(±0.02) 
    
HCSMC 
Control 1.1173(±1.98) 0.06232(±0.12) 
Wild type LPS 100 ng/ml 1.2027(±2.18)* 0.50960(±0.03) 
P. gingivalis LPS1435 100 ng/ml 1.1292(±2.36)* 0.44312(±0.03) 
P. gingivalis LPS1690 100 ng/ml 1.2017(±2.22)* 0.27231(±0.03) 
E. coli LPS 100 ng/ml 1.1677(±2.12)* 0.14220(±0.03) 
 




shown to activate the NF-kB pathway in human 
endothelial cells (Chen et al., 2007), and they could also 
induce E-selectin protein expression to a significant level 
(Darveau et al., 1995). In  this  study,  we  applied  the  P.



































Effects of   HCSMC (72 h) 




Table 2. Expression levels (mean±SD) of cytokines and cardiac biomarkers. 
 
Time (h) Group 
Biomarker 
LDH NT pro-BNP CK-MB IL-1β IL-6 IL-10 
48 
Control 60.18(±1.48) 70.01(±1.72) 0.18(±0.004) 45.46(±0.64) 101.38(±1.42) 15.61(±0.22) 
Wild type LPS 100 ng/ml 76.55(±1.88)* 218.16(±5.36)* 0.53(±0.013)* 92.07(±1.29)* 239.96(±15.19)* 16.89(±0.41) 
P. gingivalis LPS1435 100 ng/ml 109.51(±2.69)* 117.48(±2.89)* 0.23(±0.007)* 53.15(±0.61)* 205.46(±2.88)* 15.68(±0.22) 
P. gingivalis LPS1690 100 ng/ml 98.88(±2.43)* 120.88(±2.97)* 0.29(±0.007)* 54.17(±0.99)* 291.59(±6.40)* 16.64(±0.23) 
E. coli LPS 100 ng/ml 78.23(±1.92)* 287.35(±7.06)* 0.69(±0.017)* 138.33(±2.51)* 396.33(±6.16)* 17.19(±0.47) 
        
72 
Control 63.19(±1.55) 82.55(±2.03) 0.20(±0.005) 50.87(±0.71) 106.72(±1.49) 15.62(±0.22) 
Wild type LPS 100 ng/ml 138.20(±3.39)* 200.30(±4.92)* 0.48(±0.012)* 96.10(±1.35)* 269.79(±25.26)* 17.24(±0.31) 
P. gingivalis LPS1435 100 ng/ml 122.27(±3.003)* 140.55(±3.45)* 0.34(±0.008)* 54.85(±0.64)* 208.52(±2.92)* 17.64(±1.28) 
P. gingivalis LPS1690 100 ng/ml 96.75(±2.38)* 215.08(±5.28)* 0.52(±0.013)* 55.70(±0.86)* 257.42(±9.41)* 16.67(±0.23) 
E. coli LPS 100 ng/ml 75.17(±1.36)* 318.75(±7.83)* 0.76(±0.019)* 175.60(±3.23)* 572.25(±8.79)* 20.61(±0.29) 
Normal range/Unit 240-480 U/L 140-320 pg/ ml <6.73 ng/ml 15.6-500 pg/ml 2-200 pg/ml 5-400 pg/ml 
 
*Significant difference from the control, P<0.05. LDH, Lactate dehydrogenase; CK-MB, the MB isoenzyme of creatine kinase; NT pro-BNP, N-terminal pro B-type 




gingivalis wild type LPS, P. gingivalis LPS1435, 
LPS1690 and E. coli LPS to two cardiac cells, the 
results showed that LPSs could promote the cell 
proliferation of HCFs and HCSMCs. LPS induces 
a higher level of LDH, pro-BNP and CK-MB 
expression after 48 and 72 h of incubation which 
indicated that both HCFs and HCSMCs are under 
cell injury (Tables 2 and 3). In this study, we 
applied pro-BNP, a sensitive cardiac marker to 
monitor cardiac cells damage (Heeschen et al., 
2004; Tello-Montoliu et al., 2007; Kaski et al., 
2010). A combination of pro-BNP, LDH and CK-
MB may be useful to check for cardiovascular 
diseases, as these levels are often increased in 
those diseases (Heeschen et al., 2004; Tello-
Montoliu et al., 2007; Kaski et al., 2010). The pro-
BNP appears to be a unifying feature that is 
independent of other biochemical markers (myo-
cardial necrosis, inflammation) and is a powerful 
and independent determinant of the short-term 
cardiac risk in patients with acute coronary 
syndromes (Heeschen et al., 2004; Tello-Montoliu 
et al., 2007; Kaski et al., 2010). Serial measure-
ments of pro-BNP in patients with cardiac 
diseases may be used for more rapid identification 
in early stages (Heeschen et al., 2004; Tello-
Montoliu et al., 2007; Kaski et al., 2010). 
In addition, the results indicated that LPS could 
induce IL-1β and IL-6 in a time dependent fashion 
except for IL-10 (Tables 2 and 3). Therefore, 
these results matched with the findings of Roberts 
et al. (1997) that LPS could markedly induce 
inflammatory responses in HCFs and HCSMCs 
along with a proliferation state, but they may 
cause cardiac cell death leading to an expression 
of higher amount of cardiac markers (Roberts et 
al., 1997). Cardiac markers are biomarkers to 
evaluate cardiac function. Our results demon-
strated that the two kinds of cardiac cells had 
been in a phase of impaired condition (Tables 2 
and 3). The level of LPS-induced CK-MB and LDH 
increased from 48 to 72 h compared with the 
control group. In addition, the L-lactate dehydro-
genase (LDH) was also applied to determine 
cardiac cell injury in the current in vitro experi-
ments. 
Our finding is similar to the previous reports that 
the cardiac cells damage or death is associated 
with the release of a panel of cardiac markers 
(Atisha et al., 2004; Wallimann and Hemmer, 
1994; Wang et al., 2007; Totlandsdal et al., 2008). 
Even though there are some clinical or 
experimental surveys on the heart injury cor-
related with several cardiac bio-markers along 
with 1 or 2 cytokines (Kofidis et al., 2008; Nesher 
et al., 2006; Serrano et al., 2010; Zhou et al., 
2010), our study was the first to combine a panel 
of cardiac markers and a group of inflammatory 
cytokines (IL-1b, IL-6 and IL-10) to assess LPSs’ 
effect on HCFs and HCSMCs. Some previous 




Table 3. Expression levels (mean±SD) of cytokines and cardiac biomarkers. 
 
Time (h) Group 
Biomarker 
LDH NT pro-BNP CK-MB IL-1β IL-6 IL-10 
48 
Control 39.18(±0.96) 44.16(±1.09) 0.11(±0.003) 106.37(±1.25) 208.28(±6.61) 15.87(±0.22) 
Wild type LPS 100 ng/ml 93.56(±2.30)* 59.88(±1.47)* 0.14(±0.004)* 410.79(±5.75)* 280.94(±3.93)* 17.85(±1.39) 
P. gingivalis LPS1435 100 ng/ml 78.68(±1.93)* 76.97(±1.89)* 0.18(±0.005)* 118.25(±2.07)* 224.65(±2.94)* 16.81(±0.32) 
P. gingivalis LPS1690 100 ng/ml 85.05(±2.09)* 87.96(±2.16)* 0.21(±0.005)* 366.12(±6.40)* 238.85(±3.91)* 16.04(±1.36) 
E. coli LPS 100 ng/ml 58.17(±1.43)* 72.69(±1.79)* 0.17(±0.004)* 475.58(±6.66)* 293.84(±11.74)* 16.43(±0.23) 
        
72 
Control 40.12(±0.99) 40.92(±1.01) 0.10(±0.002) 104.31(±1.49) 148.89(±3.72) 16.26(±0.23) 
Wild type LPS 100 ng/ml 74.42(±1.83)* 65.93(±1.62)* 0.16(±0.004)* 488.05(±6.83)* 167.69(±4.14)* 16.71(±0.20) 
P. gingivalis LPS1435 100 ng/ml 77.61(±1.91)* 89.43(±2.20)* 0.21(±0.005)* 130.34(±1.63)* 216.71(±3.03)* 17.03(±0.52) 
P. gingivalis LPS1690 100 ng/ml 62.73(±1.54)* 90.46(±2.22)* 0.22(±0.005)* 397.57(±4.60)* 214.40(±3.00)* 17.70(±0.79) 
E. coli LPS 100 ng/ml 44.13(±1.08)* 78.02(±1.92)* 0.19(±0.005)* 488.78(±6.84)* 225.27(±13.44)* 16.13(±0.23) 
Normal range/Unit 240-480 U/L 140-320 pg/ ml <6.73 ng/ml 15.6-500 pg/ml 2-200 pg/ml 5-400 pg/ml 
 
*Significant difference from the control, P<0.05; LDH, lactate dehydrogenase; CK-MB, the MB isoenzyme of creatine kinase; NT pro-BNP, N-terminal pro B-type 
natriuretic peptide; E. coli: Escherichia coli; LPS, lipopolysaccharides. 
 
 
reports showed that different forms of LPS have 
different effects on cells (Darveau et al., 1995; 
Roberts et al., 1997; Chen et al., 2007; Lu et al., 
2009) but our results presented here did not 
demonstrate differences among the LPSs treating 
the cardiac cells in vitro. 
It is arguable that the presence of the LPS is 
beneficial to fibroblasts and smooth muscle cells 
as elevated levels of IL-1β cause increased levels 
of cell proliferation and increased levels of IL-6 
cause increased production of B cells to fight off 
disease with increased levels of IL-10, to condone 
the increased level of inflammation. In sum-mary, 
various isoforms of LPS including P. gingivalis 
wild type LPS, P. gingivalis LPS1435, LPS1690 and 
E. coli LPS affect the activity, cytokines expres-
sion and cardiac bio-markers of HCFs and 
HCMSCs at a time dependent pattern that im-
plicated the LPSs may cause certain damage to 
cardiac tissues in vivo. 
Abbreviations  
 
LPS, Lipopolysaccharide; HCFs, human cardiac 
fibroblasts; HCSMCs, human coronary smooth 
muscle cells; pro-BNP, N-terminal pro B-type 
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